Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are a promising platform for off-the-shelf immunotherapy due to their safety advantages over CAR-T cells, including lower risk of graft-versus-host disease, cytokine release syndrome, and neurotoxicity. However, their persistence a...
Saved in:
Main Author: | Hyunyoung Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Biomolecules |
Subjects: | |
Online Access: | https://www.mdpi.com/2218-273X/15/7/935 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01) -
<i>shp-2</i> gene knockout upregulates CAR-driven cytotoxicity of YT NK cells
by: V. G. Subrakova, et al.
Published: (2020-03-01) -
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
by: Yunjia Xian, et al.
Published: (2025-06-01) -
Does a natural killer need a CAR?
by: Kangbo Wang, et al.
Published: (2025-06-01) -
PECULIARITIES OF NK CELLS DIFFERENTIATION: CD56dim AND CD56bright NK CELLS AT PREGNANCY AND IN NON-PREGNANT STATE
by: V. A. Mikhailova, et al.
Published: (2017-01-01)